<DOC>
	<DOC>NCT02216266</DOC>
	<brief_summary>Evaluation if physostigmine reduces symptoms in patients who has developed a delirium in Intensive care after a surgery</brief_summary>
	<brief_title>Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery</brief_title>
	<detailed_description />
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Physostigmine</mesh_term>
	<criteria>Patients of both genders aged &gt; 18 years, &lt; 85 years of ICU C1 after elective or emergency heart surgery with or without extracorporeal circulation (heartlung machine and/or extracorporeal membrane oxygenation), with suspected delirium. (May be suspected if a patient does not show adequate improvement of vigilance 24 h after adequate reduction or stop of sedative medicine) Patients (&gt;18a, &lt;85a) with CAMICU diagnosed delirium Patients of legal capacity and patients with appointed representative Asthma hypersensitivity against Physostigmine salicylate, Sodium metabisulfite, Nitrogen gangrene mechanical obstipation mechanical urinary retention Dystrophia myotonica Depolarization block after depolarising muscle relaxants Intoxications with "irreversibly acting" cholinesterase inhibitors closed head trauma obstructions at gastrointestinal tract and at urinary tract neurological diseases left ventricular ejection fraction &lt; 40% Simultaneous Participation in other clinical trials or participation ind other clinical trials in the last 30 days untreated coronary heart disease wish to have children, pregnancy or nursing patients with addictive disorder in medical history</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Delirium</keyword>
	<keyword>CAM-ICU</keyword>
</DOC>